Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Poliomyelitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H2 2016, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape. Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 2, 5 and 7 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively. Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Poliomyelitis Overview 9 Therapeutics Development 10 Pipeline Products for Poliomyelitis - Overview 10 Pipeline Products for Poliomyelitis - Comparative Analysis 11 Poliomyelitis - Therapeutics under Development by Companies 12 Poliomyelitis - Therapeutics under Investigation by Universities/Institutes 14 Poliomyelitis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Poliomyelitis - Products under Development by Companies 18 Poliomyelitis - Products under Investigation by Universities/Institutes 20 Poliomyelitis - Companies Involved in Therapeutics Development 21 Beijing Minhai Biotechnology Co Ltd 21 Beijing Tiantan Biological Products Co Ltd 22 Bharat Biotech International Ltd 23 Biken Inc 24 Bilthoven Biologicals BV 25 Biological E Ltd 26 Boryung Pharmaceutical Co Ltd 27 Codagenix Inc 28 Daiichi Sankyo Company Ltd 29 GlaxoSmithKline Plc 30 Grifols SA 31 Johnson & Johnson 32 Kaketsuken KK 33 LG Life Science LTD 34 Nanolek 35 Panacea Biotec Ltd 36 Sanofi Pasteur SA 37 Sentinext Therapeutics Sdn Bhd 38 Shantha Biotechnics Ltd 39 Taiga Biotechnologies Inc 40 Takeda Pharmaceutical Company Ltd 41 Poliomyelitis - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 (diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 BVN-002 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 immune globulin (human) - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 ImmunoRx - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 IPVGVI-3000 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 KD-370 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 LBVC - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 LBVD - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 polio (virus like particle, bivalent) vaccine - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 polio [strain Sabin] vaccine - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 polio vaccine - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 polio vaccine - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 polio vaccine - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 polio vaccine - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 polio vaccine - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 polio vaccine - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 poliomyelitis vaccine - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 TAK-195 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 VN-0105 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Poliomyelitis - Dormant Projects 80 Poliomyelitis - Discontinued Products 81 Poliomyelitis - Product Development Milestones 82 Featured News & Press Releases 82 Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate 82 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables
Number of Products under Development for Poliomyelitis, H2 2016 10 Number of Products under Development for Poliomyelitis - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H2 2016 20 Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 21 Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016 22 Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H2 2016 23 Poliomyelitis - Pipeline by Biken Inc, H2 2016 24 Poliomyelitis - Pipeline by Bilthoven Biologicals BV, H2 2016 25 Poliomyelitis - Pipeline by Biological E Ltd, H2 2016 26 Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 27 Poliomyelitis - Pipeline by Codagenix Inc, H2 2016 28 Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 29 Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H2 2016 30 Poliomyelitis - Pipeline by Grifols SA, H2 2016 31 Poliomyelitis - Pipeline by Johnson & Johnson, H2 2016 32 Poliomyelitis - Pipeline by Kaketsuken KK, H2 2016 33 Poliomyelitis - Pipeline by LG Life Science LTD, H2 2016 34 Poliomyelitis - Pipeline by Nanolek, H2 2016 35 Poliomyelitis - Pipeline by Panacea Biotec Ltd, H2 2016 36 Poliomyelitis - Pipeline by Sanofi Pasteur SA, H2 2016 37 Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016 38 Poliomyelitis - Pipeline by Shantha Biotechnics Ltd, H2 2016 39 Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H2 2016 40 Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 41 Assessment by Monotherapy Products, H2 2016 42 Assessment by Combination Products, H2 2016 43 Number of Products by Stage and Target, H2 2016 45 Number of Products by Stage and Route of Administration, H2 2016 47 Number of Products by Stage and Molecule Type, H2 2016 49 Poliomyelitis - Dormant Projects, H2 2016 80 Poliomyelitis - Discontinued Products, H2 2016 81
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
